About 20 to 30 percent of women with breast cancer have tumors that are missed by mammogram screening. These interval breast cancers – discovered between routine mammograms – seem to be more...
There is a big gap between the narrowly focused data gathered in clinical trials and the lower-quality but more plentiful “real world" data routinely collected in clinical records, insurance claims...
The survival rate for all cancers combined more than doubled since the 1960s, a testament to the power of clinical trials that test new treatments in volunteers. But big challenges loom. Pictured...
Knight Cancer researchers describe positive results with the drug regorafenib. Osteosarcoma is a bone cancer that disproportionately affects teenagers, and despite substantial efforts, outcomes for...
Cancer clinical trials that use less-reliable shortcut endpoints save relatively little time, according to an analysis of 107 cancer drugs approved for 188 indications from 2006 to 2017. Image:...
The Beat AML clinical trial has matched 250 study participants to targeted treatments for acute myeloid leukemia – with promising early results. Regulators were wary of the complicated study...
The VA Portland Health Care System is one of 12 centers across the U.S. selected for a national initiative to give military veterans more opportunities to participate in cancer clinical trials. The...
Osteosarcoma is a bone cancer that disproportionately affects teenagers, and outcomes for patients have changed little in decades. Now researchers, including two OHSU Knight Cancer Institute...
Q&A: Prostate cancer expert Julie Graff, M.D., explains how a new treatment option fills a void for men with resurgent tumors. When prostate cancer isn't cured by surgery or radiation, the...
A $10 million gift from The Harry T. Mangurian Jr. Foundation will help The Leukemia & Lymphoma Society expand the Beat AML Master Trial underway at the OHSU Knight Cancer Institute and other...
Five oncologists at Oregon Health & Science University in Portland will receive a $25,000 salary supplement for one year, allowing them to reserve time to pursue promising research...